Onco360 becomes national pharmacy partner for Revuforj, the first approved drug for specific acute leukemias.

Onco360, a specialty pharmacy, has been chosen as the national pharmacy partner for Revuforj (revumenib), the first approved menin inhibitor for treating relapsed or refractory acute leukemias with KMT2A gene translocations in patients aged 1 and older. The FDA approval is based on a trial showing a 21.2% complete remission rate. Revuforj comes in tablets and an oral solution for younger patients, with a boxed warning for differentiation syndrome.

November 20, 2024
6 Articles

Further Reading